secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001544227-22-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Q3 2022 net loss $8.9M; cash at $42.8M; pipeline milestones on track
----------------------------------------------------------------------------

- Cash and equivalents $42.8M as of Sep 30, 2022, down from $51.8M at Dec 31, 2021.
- Net loss Q3 2022 of $8.9M ($0.66/sh) vs $8.1M ($1.21/sh) in Q3 2021.
- R&D expense increased to $6.0M from $4.6M on expanded R&D efforts.
- TPST-1120 Phase 1b/2 HCC study with Roche; early data from first 40 patients expected H1 2023.
- TPST-1495 Phase 1 dose optimization data expected by year-end or early 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000154422722000004/0001544227-22-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000154422722000004/tpst-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001544227-22-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer